Schnitzler syndrome is a rare autoinflammatory systemic disease, whose characteristic features are typically chronic urticaria and monoclonal gammopathy. Over 300 cases have been reported worldwide since its discovery, more frequently in Europe than other regions such as North America, Japan, and Latin America. No predisposing conditions or inheritance pattern associated with this disease have been identified to date. However, it seems that disruption of interleukin 1 homeostasis plays an important role as the main pathophysiological mechanism. The main complications described associated with this disease are malignant lymphoproliferative disorders or the development of amyloidosis. Treatment consists primarily of interleukin 1 blockade and this has shown significant control of clinical symptoms. In this review we aim to take an in-depth look at the possible pathophysiological mechanisms of this rare entity.
{"title":"Síndrome de Schnitzler: una mirada profunda a un trastorno médico raro","authors":"Luisa Fernanda Jiménez Arcia , Gloria Vásquez Duque","doi":"10.1016/j.rcreu.2024.11.005","DOIUrl":"10.1016/j.rcreu.2024.11.005","url":null,"abstract":"<div><div>Schnitzler syndrome is a rare autoinflammatory systemic disease, whose characteristic features are typically chronic urticaria and monoclonal gammopathy. Over 300 cases have been reported worldwide since its discovery, more frequently in Europe than other regions such as North America, Japan, and Latin America. No predisposing conditions or inheritance pattern associated with this disease have been identified to date. However, it seems that disruption of interleukin 1 homeostasis plays an important role as the main pathophysiological mechanism. The main complications described associated with this disease are malignant lymphoproliferative disorders or the development of amyloidosis. Treatment consists primarily of interleukin 1 blockade and this has shown significant control of clinical symptoms. In this review we aim to take an in-depth look at the possible pathophysiological mechanisms of this rare entity.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"33 1","pages":"Article 102164"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147409806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-03-24DOI: 10.1016/j.rcreu.2025.01.001
Eva Álvarez Andrés , Eugenio de Miguel , Laura Nuño Nuño , Paloma García de la Peña Lefebvre , Itsaso Losantos , Alejandro Balsa , Paloma Turiel , Nuria Garvin , Manuel Beladiez , Camila Tapia , Cristina Zamora , Ana Belén Rodriguez , Clara Sangüesa , Patricia López , Rocío Mustienes , Ana Cruz
Objectives
Nailfold capillaroscopy (CP) is used in the study of Raynaud's phenomenon (RPh). Many people have cardiovascular risk factors (CVRF): tobacco (TOB), diabetes (DM), alcohol (ALC), dyslipidaemia (DL), arterial hypertension (HT), and obesity (OBE). The objective of the work was to investigate whether CVRF produce capillaroscopic alterations, which could influence their final interpretation.
Methods
Multicentre descriptive retrospective study of patients referred to CP consultation for RPh or suspected connective tissue disease in two Madrid hospitals between 2015 and 2018. 200x videocapillaroscopy (Dinolite®) was used. Analytical, clinical, therapeutic variables, CVRF, and capillaroscopic alterations (tortuosities, ramifications, dilations, giant capillaries, decreased density, and haemorrhages) were collected. For the statistical study, parametric and non-parametric tests were used (statistical significance at P<.05).
Results
Three hundred forty medical records were reviewed, 286 (84.1%), mean age of 52.36 ± 16.97 years; 270 had RPh (79.4%) and 212 (62.4%) CVRF: 108 TOB (31.8%), 108 DL (31.8%), 62 HT (18.2%), 20 DM (5.8%), 8 ALC (2.4%). Three groups were formed: 155 primary RPh (45.6%), 123 with connective tissue disease (36.2%) and 62 with other osteoarticular diseases (18.2%). The statistical study showed an association between all capillaroscopic alterations and CVRF (P<.001), as well as between: decreased density with HT (p = 0.006); tortuosities with HT (P<.001) and hypercholesterolaemia (P=.006); Dilations, ramifications, haemorrhages with HT (P<.001, P=.019, and P=.008) and TOB (P<.001, P=.019, and P=.002); giant capillaries with TOB (P=.034).
Conclusions
This work shows the association between capillaroscopic alterations and CVRF, which should be considered for correct CP interpretation.
{"title":"¿Pueden los factores de riesgo cardiovascular afectar al resultado de la capilaroscopia? Estudio retrospectivo multicéntrico","authors":"Eva Álvarez Andrés , Eugenio de Miguel , Laura Nuño Nuño , Paloma García de la Peña Lefebvre , Itsaso Losantos , Alejandro Balsa , Paloma Turiel , Nuria Garvin , Manuel Beladiez , Camila Tapia , Cristina Zamora , Ana Belén Rodriguez , Clara Sangüesa , Patricia López , Rocío Mustienes , Ana Cruz","doi":"10.1016/j.rcreu.2025.01.001","DOIUrl":"10.1016/j.rcreu.2025.01.001","url":null,"abstract":"<div><h3>Objectives</h3><div>Nailfold capillaroscopy (CP) is used in the study of Raynaud's phenomenon (RPh). Many people have cardiovascular risk factors (CVRF): tobacco (TOB), diabetes (DM), alcohol (ALC), dyslipidaemia (DL), arterial hypertension (HT), and obesity (OBE). The objective of the work was to investigate whether CVRF produce capillaroscopic alterations, which could influence their final interpretation.</div></div><div><h3>Methods</h3><div>Multicentre descriptive retrospective study of patients referred to CP consultation for RPh or suspected connective tissue disease in two Madrid hospitals between 2015 and 2018. 200x videocapillaroscopy (Dinolite®) was used. Analytical, clinical, therapeutic variables, CVRF, and capillaroscopic alterations (tortuosities, ramifications, dilations, giant capillaries, decreased density, and haemorrhages) were collected. For the statistical study, parametric and non-parametric tests were used (statistical significance at <em>P</em><.05).</div></div><div><h3>Results</h3><div>Three hundred forty medical records were reviewed, 286 (84.1%), mean age of 52.36<!--> <!-->±<!--> <!-->16.97 years; 270 had RPh (79.4%) and 212 (62.4%) CVRF: 108 TOB (31.8%), 108 DL (31.8%), 62 HT (18.2%), 20 DM (5.8%), 8 ALC (2.4%). Three groups were formed: 155 primary RPh (45.6%), 123 with connective tissue disease (36.2%) and 62 with other osteoarticular diseases (18.2%). The statistical study showed an association between all capillaroscopic alterations and CVRF (<em>P</em><.001), as well as between: decreased density with HT (p<!--> <!-->=<!--> <!-->0.006); tortuosities with HT (<em>P</em><.001) and hypercholesterolaemia (<em>P</em>=.006); Dilations, ramifications, haemorrhages with HT (<em>P</em><.001, <em>P</em>=.019, and <em>P</em>=.008) and TOB (<em>P</em><.001, <em>P</em>=.019, and <em>P</em>=.002); giant capillaries with TOB (<em>P</em>=.034).</div></div><div><h3>Conclusions</h3><div>This work shows the association between capillaroscopic alterations and CVRF, which should be considered for correct CP interpretation.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"33 1","pages":"Article 102171"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147410786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-01-30DOI: 10.1016/j.rcreu.2024.11.003
Pablo Arango Guerra , Alejandro Echavarría Cross , Manuel Alejandro Giraldo Delgado , Mauricio Murillo Moreno , María Pérez-Restrepo , Juan Camilo Díaz-Coronado , Diego Fernando Rojas-Gualdrón , Neil Pertuz
Introduction
Disease relapses of idiopathic inflammatory myopathies (IIM) play a significant role in the burden of disease. However, Colombian studies with long-term follow-ups are scarce.
Objective
To estimate the ten-year relapse-free survival in patients with idiopathic inflammatory myopathy treated at a specialized medical centre for autoimmune diseases with presence in different cities in Colombia.
Method
This is a retrospective follow-up study based on medical records. All patients diagnosed with idiopathic inflammatory myopathy treated between January 2012 and June 2022 were included. The time to relapse was defined as the outcome variable. Additionally, demographic, clinical, laboratory, and treatment variables were characterized. Analyses were performed using Weibull survival regression for interval-censored data.
Results
A total of 278 patients followed for a mean of 6.60 years were included. Of these, 70.9% were women, with a median age of 57 (IQR 40-66) years. Dermatomyositis (60.1%) and polymyositis (28.1%) were the most frequent phenotypes. Relapse-free survival at one year was 86.3%, and at 5 years, 68.3%, with a median relapse-free time of 13.8 years. By phenotype, the lowest median relapse-free survival rates were observed for antisynthetase syndrome at 3 years, immune-mediated necrotizing myopathy at 6 years, and juvenile dermatomyositis at 7.3 years.
Conclusion
Relapse-free survival is highly heterogeneous according to the clinical phenotype of idiopathic inflammatory myopathy, being lowest in patients with antisynthetase syndrome.
{"title":"Recaída de la enfermedad en miopatías inflamatorias idiopáticas: un estudio multicéntrico de 10 años de seguimiento basado en registros en Colombia","authors":"Pablo Arango Guerra , Alejandro Echavarría Cross , Manuel Alejandro Giraldo Delgado , Mauricio Murillo Moreno , María Pérez-Restrepo , Juan Camilo Díaz-Coronado , Diego Fernando Rojas-Gualdrón , Neil Pertuz","doi":"10.1016/j.rcreu.2024.11.003","DOIUrl":"10.1016/j.rcreu.2024.11.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Disease relapses of idiopathic inflammatory myopathies (IIM) play a significant role in the burden of disease. However, Colombian studies with long-term follow-ups are scarce.</div></div><div><h3>Objective</h3><div>To estimate the ten-year relapse-free survival in patients with idiopathic inflammatory myopathy treated at a specialized medical centre for autoimmune diseases with presence in different cities in Colombia.</div></div><div><h3>Method</h3><div>This is a retrospective follow-up study based on medical records. All patients diagnosed with idiopathic inflammatory myopathy treated between January 2012 and June 2022 were included. The time to relapse was defined as the outcome variable. Additionally, demographic, clinical, laboratory, and treatment variables were characterized. Analyses were performed using Weibull survival regression for interval-censored data.</div></div><div><h3>Results</h3><div>A total of 278 patients followed for a mean of 6.60 years were included. Of these, 70.9% were women, with a median age of 57 (IQR 40-66) years. Dermatomyositis (60.1%) and polymyositis (28.1%) were the most frequent phenotypes. Relapse-free survival at one year was 86.3%, and at 5<!--> <!-->years, 68.3%, with a median relapse-free time of 13.8 years. By phenotype, the lowest median relapse-free survival rates were observed for antisynthetase syndrome at 3 years, immune-mediated necrotizing myopathy at 6 years, and juvenile dermatomyositis at 7.3 years.</div></div><div><h3>Conclusion</h3><div>Relapse-free survival is highly heterogeneous according to the clinical phenotype of idiopathic inflammatory myopathy, being lowest in patients with antisynthetase syndrome.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"33 1","pages":"Article 102162"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147410787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-02-10DOI: 10.1016/j.rcreu.2024.11.002
Leosirlay Rojas-Gómez , Adriana Díaz-Maldonado , María Fernanda Reina-Ávila
Juvenile systemic lupus erythematosus is a chronic, autoimmune, and multisystemic disease that affects individuals under 18 years of age. Its early onset suggests a strong genetic relationship, with identified genetic variants causing monogenic systemic lupus erythematosus. The case of a 10-year-old patient with juvenile systemic lupus erythematosus is reported, presenting atypically, severely, and with failure to respond to standard treatment, in whom a variant in the TREX1 gene c.590C>T, p.Ala197Val was identified. TREX1 variants represent up to 2% of systemic lupus erythematosus cases and should be considered in children with early onset, atypical, and severe presentation.
{"title":"Variante de TREX1 c.590C>T como causa de lupus eritematoso sistémico monogénico en niña de 10 años: reporte de caso","authors":"Leosirlay Rojas-Gómez , Adriana Díaz-Maldonado , María Fernanda Reina-Ávila","doi":"10.1016/j.rcreu.2024.11.002","DOIUrl":"10.1016/j.rcreu.2024.11.002","url":null,"abstract":"<div><div>Juvenile systemic lupus erythematosus is a chronic, autoimmune, and multisystemic disease that affects individuals under 18 years of age. Its early onset suggests a strong genetic relationship, with identified genetic variants causing monogenic systemic lupus erythematosus. The case of a 10-year-old patient with juvenile systemic lupus erythematosus is reported, presenting atypically, severely, and with failure to respond to standard treatment, in whom a variant in the TREX1 gene c.590C>T, p.Ala197Val was identified. TREX1 variants represent up to 2% of systemic lupus erythematosus cases and should be considered in children with early onset, atypical, and severe presentation.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"33 1","pages":"Article 102161"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147409802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-03-22DOI: 10.1016/j.rcreu.2025.01.003
Paul J. Tejada-Llacsa , Julia Sumire Umes , Manuel Francisco Ugarte-Gil , Graciela S. Alarcón , Víctor Román Pimentel-Quiroz
Introduction
Polyarteritis nodosa is a rare form of vasculitis which affects medium and small arteries. Gastrointestinal involvement occurs in 14–65% of patients, the most common symptom being abdominal pain; in a few cases, intestinal perforation may occur. Chronic diarrhea at disease onset is, however, very uncommon.
Objective
To present the case of an elderly man with chronic diarrhea as the main manifestation of polyarteritis nodosa that progressed to intestinal perforation.
Material and methods
The diagnosis of polyarteritis nodosa was made by intestinal biopsy; cyclophosphamide was administered as induction treatment with progressive clinical improvement. Furthermore, a PubMed literature review was conducted.
Results
Three communications on which diarrhea was reported as a manifestation of polyarteritis nodosa; in one of these patients, a 13-year-old girl, chronic diarrhea was the main manifestation.
Conclusion
This case illustrates the diagnostic complexity of polyarteritis nodosa due to non-specific symptoms and atypical presentation such as diarrhea, underscoring the importance for early recognition and intervention.
{"title":"Chronic diarrhea as initial manifestation of polyarteritis nodosa: A case-based review","authors":"Paul J. Tejada-Llacsa , Julia Sumire Umes , Manuel Francisco Ugarte-Gil , Graciela S. Alarcón , Víctor Román Pimentel-Quiroz","doi":"10.1016/j.rcreu.2025.01.003","DOIUrl":"10.1016/j.rcreu.2025.01.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Polyarteritis nodosa is a rare form of vasculitis which affects medium and small arteries. Gastrointestinal involvement occurs in 14–65% of patients, the most common symptom being abdominal pain; in a few cases, intestinal perforation may occur. Chronic diarrhea at disease onset is, however, very uncommon.</div></div><div><h3>Objective</h3><div>To present the case of an elderly man with chronic diarrhea as the main manifestation of polyarteritis nodosa that progressed to intestinal perforation.</div></div><div><h3>Material and methods</h3><div>The diagnosis of polyarteritis nodosa was made by intestinal biopsy; cyclophosphamide was administered as induction treatment with progressive clinical improvement. Furthermore, a PubMed literature review was conducted.</div></div><div><h3>Results</h3><div>Three communications on which diarrhea was reported as a manifestation of polyarteritis nodosa; in one of these patients, a 13-year-old girl, chronic diarrhea was the main manifestation.</div></div><div><h3>Conclusion</h3><div>This case illustrates the diagnostic complexity of polyarteritis nodosa due to non-specific symptoms and atypical presentation such as diarrhea, underscoring the importance for early recognition and intervention.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"33 1","pages":"Article 102174"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147409803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease associated with the chronic inflammatory state.
Objective
The objective was to describe arterial stiffness in RA patients with low disease activity and its relationship with cardiovascular risk factors.
Materials and methods
Case series study. Consecutive inclusion of patients with RA in low disease activity. Sociodemographic, clinical and laboratory data, and disease activity score-28 were captured. Arterial stiffness (pulse wave velocity [PWV], oscillometric method) was assessed. Univariate and bivariate analyses, correlations (rho Spearman), and principal component analysis.
Results
52 patients (76.9% women) were included. Median age 57 years (interquartile range [IQR] 9). Median disease activity score-28 (DAS28) 2.6 (IQR-1.3), low activity. Mean PWV 8.45 (Standard deviation 3.1) m/sec. PWV in patients treated with methotrexate was lower (P = .013). Age was correlated with PWV (P = .006). Aortic augmentation index was higher in women (P = .015) and in patients with familial autoimmunity (P = .05). Framingham cardiovascular risk score correlated with pulse pressures. The number of cups of coffee consumed was correlated (inversely) with the aortic augmentation index (P = .042). Principal component analysis (4 components) explained 70.1% of the variance.
Conclusions
PWV levels in patients with RA in low disease activity were similar to those reported in the population without RA. Despite not being elevated, they correlate with traditional and non-traditional cardiovascular risk factors (methotrexate, familial autoimmunity, coffee consumption).
{"title":"Factores de riesgo cardiovascular relacionados con rigidez arterial en pacientes con artritis reumatoide en actividad baja de la enfermedad","authors":"Gabriel-Santiago Rodríguez-Vargas , Jaime-Andrés Rubio-Rubio , Pedro Santos-Moreno , Darío Echeverri , Luz-Dary Gutiérrez-Castañeda , Paula-Katherine Bautista-Niño , Adriana Rojas-Villarraga","doi":"10.1016/j.rcreu.2024.06.004","DOIUrl":"10.1016/j.rcreu.2024.06.004","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease associated with the chronic inflammatory state.</div></div><div><h3>Objective</h3><div>The objective was to describe arterial stiffness in RA patients with low disease activity and its relationship with cardiovascular risk factors.</div></div><div><h3>Materials and methods</h3><div>Case series study. Consecutive inclusion of patients with RA in low disease activity. Sociodemographic, clinical and laboratory data, and disease activity score-28 were captured. Arterial stiffness (pulse wave velocity [PWV], oscillometric method) was assessed. Univariate and bivariate analyses, correlations (rho Spearman), and principal component analysis.</div></div><div><h3>Results</h3><div>52 patients (76.9% women) were included. Median age 57<!--> <!-->years (interquartile range [IQR] 9). Median disease activity score-28 (DAS28) 2.6 (IQR-1.3), low activity. Mean PWV 8.45 (Standard deviation 3.1) m/sec. PWV in patients treated with methotrexate was lower (<em>P</em> <!-->=<!--> <!-->.013). Age was correlated with PWV (<em>P</em> <!-->=<!--> <!-->.006). Aortic augmentation index was higher in women (<em>P</em> <!-->=<!--> <!-->.015) and in patients with familial autoimmunity (<em>P</em> <!-->=<!--> <!-->.05). Framingham cardiovascular risk score correlated with pulse pressures. The number of cups of coffee consumed was correlated (inversely) with the aortic augmentation index (<em>P</em> <!-->=<!--> <!-->.042). Principal component analysis (4 components) explained 70.1% of the variance.</div></div><div><h3>Conclusions</h3><div>PWV levels in patients with RA in low disease activity were similar to those reported in the population without RA. Despite not being elevated, they correlate with traditional and non-traditional cardiovascular risk factors (methotrexate, familial autoimmunity, coffee consumption).</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"33 1","pages":"Article 102146"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147410755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-07-16DOI: 10.1016/j.rcreu.2025.04.003
Sebastián Ospina Pérez , Evanny S. Valencia Patiño , Daniel Efrén Rodríguez Ariza , Juan C. Díaz Coronado , Carolina Pérez Ríos
Introduction
Rheumatoid arthritis (RA) is an autoimmune, chronic disease with significant morbidity, often hindered by access barriers to therapy.
Objective
To assess the effect of a pharmaceutical service in an outpatient rheumatology unit that dispensed medications at the end of the consultation.
Material and methods
An observational-analytical, retrospective study tracking a cohort of RA patients (before and after the introduction of the pharmacy service). Bivariate analysis was conducted using the Chi-square test, and multivariate analysis using a regression model with the variables disease remission (DAS28 [ESR] < 2.6) and moderate-to-high RA activity (DAS28 [ESR] > 3.2).
Results
A total of 544 patients were included, of which 435 (80.0%) were female. Remission was observed in 266 (48.9%) patients before and 384 (70.6%) after implementation of the pharmaceutical service. Factors associated with RA remission included biological therapy (HR: 0.37; 95% CI: 0.25-0.56), corticosteroid therapy (HR: 0.31; 95% CI: 0.21-0.44), leflunomide (HR: 0.55; 95% CI: 0.42-0.72), sulfasalazine (HR: 0.60; 95% CI: 0.42-0.86), and having access to the pharmaceutical service (HR: 2.93; 95% CI: 2.23-3.85).
Conclusions
Implementing a pharmaceutical service that dispenses medications for rheumatoid arthritis immediately after consultation was associated with disease remission.
{"title":"Impacto de la implementación de un servicio farmacéutico en la consulta de pacientes con artritis reumatoide","authors":"Sebastián Ospina Pérez , Evanny S. Valencia Patiño , Daniel Efrén Rodríguez Ariza , Juan C. Díaz Coronado , Carolina Pérez Ríos","doi":"10.1016/j.rcreu.2025.04.003","DOIUrl":"10.1016/j.rcreu.2025.04.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Rheumatoid arthritis (RA) is an autoimmune, chronic disease with significant morbidity, often hindered by access barriers to therapy.</div></div><div><h3>Objective</h3><div>To assess the effect of a pharmaceutical service in an outpatient rheumatology unit that dispensed medications at the end of the consultation.</div></div><div><h3>Material and methods</h3><div>An observational-analytical, retrospective study tracking a cohort of RA patients (before and after the introduction of the pharmacy service). Bivariate analysis was conducted using the Chi-square test, and multivariate analysis using a regression model with the variables disease remission (DAS28 [ESR] <<!--> <!-->2.6) and moderate-to-high RA activity (DAS28 [ESR] ><!--> <!-->3.2).</div></div><div><h3>Results</h3><div>A total of 544 patients were included, of which 435 (80.0%) were female. Remission was observed in 266 (48.9%) patients before and 384 (70.6%) after implementation of the pharmaceutical service. Factors associated with RA remission included biological therapy (HR: 0.37; 95%<!--> <!-->CI: 0.25-0.56), corticosteroid therapy (HR: 0.31; 95%<!--> <!-->CI: 0.21-0.44), leflunomide (HR: 0.55; 95%<!--> <!-->CI: 0.42-0.72), sulfasalazine (HR: 0.60; 95%<!--> <!-->CI: 0.42-0.86), and having access to the pharmaceutical service (HR: 2.93; 95%<!--> <!-->CI: 2.23-3.85).</div></div><div><h3>Conclusions</h3><div>Implementing a pharmaceutical service that dispenses medications for rheumatoid arthritis immediately after consultation was associated with disease remission.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"33 1","pages":"Article 102185"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147410785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fibromyalgia has a high degree of co-occurrence with a number of conditions. The association of fibromyalgia, headache and mood disorders is well observed.
Objective
To analyze the relationship between these manifestations, exploring whether the quality of life in patients with fibromyalgia is influenced by the presence of depressive symptoms and chronification of headache.
Materials and methods
A retrospective observational cross-sectional study was carried out to determine the quality of life of patients with fibromyalgia presenting with headache and/or depressive symptoms. The samples were evaluated using the Widespread Pain Index (WPI) and Symptom Severity (SS) questionnaires to confirm the diagnosis of fibromyalgia. Quality of life and level of depressive symptoms were assessed, respectively, by the Fibromyalgia Impact Questionnaire (FIQ) and the Patient Health Questionnaire-9 (PHQ-9).
Results
A total of 120 patients (3 men and 117 women) diagnosed with fibromyalgia were interviewed, with ages ranging from 23 to 65 years. The most common primary headache was chronic migraine (45%). While depressive symptoms was observed in 118 patients (98.33%). The factors degree of depressive symptoms and headache chronicity were marginally significant in explaining the quality of life of patients with fibromyalgia.
Conclusions
Faced with a disease with such a possibility of being associated with other complex conditions, multidisciplinary monitoring becomes a preponderant factor in the treatment of the entire patient.
{"title":"Quality of life of patients with fibromyalgia presenting headache and/or depressive symptoms","authors":"Yasmine Fortes , Wallyson Souza , Adriana Soares , Maria das Graças Sousa , Bruna Castro , Raimundo Silva-Néto , Gabriela Uchôa","doi":"10.1016/j.rcreu.2024.08.001","DOIUrl":"10.1016/j.rcreu.2024.08.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Fibromyalgia has a high degree of co-occurrence with a number of conditions. The association of fibromyalgia, headache and mood disorders is well observed.</div></div><div><h3>Objective</h3><div>To analyze the relationship between these manifestations, exploring whether the quality of life in patients with fibromyalgia is influenced by the presence of depressive symptoms and chronification of headache.</div></div><div><h3>Materials and methods</h3><div>A retrospective observational cross-sectional study was carried out to determine the quality of life of patients with fibromyalgia presenting with headache and/or depressive symptoms. The samples were evaluated using the Widespread Pain Index (WPI) and Symptom Severity (SS) questionnaires to confirm the diagnosis of fibromyalgia. Quality of life and level of depressive symptoms were assessed, respectively, by the Fibromyalgia Impact Questionnaire (FIQ) and the Patient Health Questionnaire-9 (PHQ-9).</div></div><div><h3>Results</h3><div>A total of 120 patients (3 men and 117 women) diagnosed with fibromyalgia were interviewed, with ages ranging from 23 to 65 years. The most common primary headache was chronic migraine (45%). While depressive symptoms was observed in 118 patients (98.33%). The factors degree of depressive symptoms and headache chronicity were marginally significant in explaining the quality of life of patients with fibromyalgia.</div></div><div><h3>Conclusions</h3><div>Faced with a disease with such a possibility of being associated with other complex conditions, multidisciplinary monitoring becomes a preponderant factor in the treatment of the entire patient.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"33 1","pages":"Article 102152"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147410789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-07-09DOI: 10.1016/j.rcreu.2025.05.001
Laura Vela Valle , Jorge Perbech Larraz , Margarita Míriam Lesta Colmenero , Maria Patricia Solana Hidalgo , Borja del Carmelo Gracia Tello , Mercedes Pilar Pérez Conesa , Luis Sáez Comet
Introduction
Antiphospholipid antibody syndrome (APS) is characterized by the presence of thrombosis and obstetric pathology.
Objective
To analyze the diagnostic validity of the FAS classification criteria published in 2023 by the American College of Rheumatology (ACR) together with the European Alliance of Associations for Rheumatology (EULAR) and to compare them with the 2006 Sydney criteria in pregnant women with suspected APS.
Material and methods
Retrospective observational cohort study based on the follow-up of 754 pregnancies by the Autoimmune Diseases Unit of the Miguel Servet University Hospital in Zaragoza. The diagnosis of its specialist doctors was considered to be gold-standard. Sensitivity, specificity, positive and negative predictive values, and area under the curve (AUC) were calculated for the Sydney and ACR/ELAR criteria, with a value of P<.05.
Results
The 2023 ACR/EULAR classification criteria had a sensitivity of 17.47% (AUC: 0.583) compared to 74.70% (AUC: 0.871) for the Sydney criteria.
Discussion
The new ACR/EULAR 2023 criteria are more complex due to the incorporation of new evidence in antiphospholipid syndrome; However, in terms of results, we found a clearly lower sensitivity in the new criteria in agreement with the findings of other studies.
Conclusions
The diagnosis of APS continues to be a challenge, due to its multifactorial nature, high prevalence of thrombosis and pregnancy morbidity in the population, Broad range of antiphospholipid antibody and the absence of a gold-standard. The results of our study suggest a worse diagnostic performance of the ACR/EULAR criteria compared to the Sydney criteria for the classification of obstetric APS, so further studies are needed to confirm these findings.
{"title":"Comparación de los criterios de clasificación del síndrome antifosfolipídico (SAF) de ACR/EULAR 2023 vs. criterios de Sídney 2006 en una muestra de gestantes con SAF","authors":"Laura Vela Valle , Jorge Perbech Larraz , Margarita Míriam Lesta Colmenero , Maria Patricia Solana Hidalgo , Borja del Carmelo Gracia Tello , Mercedes Pilar Pérez Conesa , Luis Sáez Comet","doi":"10.1016/j.rcreu.2025.05.001","DOIUrl":"10.1016/j.rcreu.2025.05.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Antiphospholipid antibody syndrome (APS) is characterized by the presence of thrombosis and obstetric pathology.</div></div><div><h3>Objective</h3><div>To analyze the diagnostic validity of the FAS classification criteria published in 2023 by the American College of Rheumatology (ACR) together with the European Alliance of Associations for Rheumatology (EULAR) and to compare them with the 2006 Sydney criteria in pregnant women with suspected APS.</div></div><div><h3>Material and methods</h3><div>Retrospective observational cohort study based on the follow-up of 754 pregnancies by the Autoimmune Diseases Unit of the Miguel Servet University Hospital in Zaragoza. The diagnosis of its specialist doctors was considered to be gold-standard. Sensitivity, specificity, positive and negative predictive values, and area under the curve (AUC) were calculated for the Sydney and ACR/ELAR criteria, with a value of <em>P</em><.05.</div></div><div><h3>Results</h3><div>The 2023 ACR/EULAR classification criteria had a sensitivity of 17.47% (AUC: 0.583) compared to 74.70% (AUC: 0.871) for the Sydney criteria.</div></div><div><h3>Discussion</h3><div>The new ACR/EULAR 2023 criteria are more complex due to the incorporation of new evidence in antiphospholipid syndrome; However, in terms of results, we found a clearly lower sensitivity in the new criteria in agreement with the findings of other studies.</div></div><div><h3>Conclusions</h3><div>The diagnosis of APS continues to be a challenge, due to its multifactorial nature, high prevalence of thrombosis and pregnancy morbidity in the population, Broad range of antiphospholipid antibody and the absence of a gold-standard. The results of our study suggest a worse diagnostic performance of the ACR/EULAR criteria compared to the Sydney criteria for the classification of obstetric APS, so further studies are needed to confirm these findings.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"33 1","pages":"Article 102189"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147409775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号